Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015)

Travere Therapeutics (TVTX) posted Non-Current Debt of $40.8 million for Q1 2015, up 1.6% on a QoQ basis from $40.2 million in Q3 2014.

Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015) Analysis & Trends

Travere Therapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $40.8 million for Q1 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 105.94 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 842.92 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Travere Therapeutics 5.21 Bn 5.21 Bn 125.25 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2015 40.80 Mn
Sep 30, 2014 40.16 Mn